Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 12:51 PM ET


Company Overview of Hetero Drugs Limited

Company Overview

Hetero Drugs Limited, a pharmaceutical company, develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediate chemicals, and generic finished dosages in India. The company offers APIs in the areas of antiretroviral and oncology products to the global pharmaceutical market; finished dosages in various therapeutic areas, including antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, anti-diabetics, pain management, anti-infectives, dermatology, and oncology; and oncology products, including injectables, solid/liquid oral dosages, ointments, soft gelatine capsules, and inhalers. It also develops and manufactures bio-generics; and provid...




Hyderabad,  500018


Founded in 1993


91 40 2370 4923


91 40 2370 4926

Key Executives for Hetero Drugs Limited

Founder, Chairman and Managing Director
Age: 61
Whole Time Director
Age: 58
Director of Production and Whole Time Director
Age: 46
Compensation as of Fiscal Year 2015.

Hetero Drugs Limited Key Developments

Cipla Reportedly Mulls Acquisition Of Hetero’s US Business

Cipla Limited (NSEI:CIPLA) is in talks to acquire US business of Hetero Drugs Limited, which is run under the Camber Pharmaceuticals brand, according to sources. The deal, which may be announced in the next few days, values Hetero's US business at $500-550 million and may including manufacturing facilities, sources added. When contacted by CNBC-TV18, Cipla said that it did not want to comment on any product or partner discussions and that it was "constantly in discussions with multiple partners on potential collaborations". "Our aspiration is to drive access to and ensure availability of affordable medicines," Cipla said.

Hetero Announces the Launch of Biosimilar Rituximab MABALL in India

Hetero Group announced the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India. The launch of biosimilar Rituximab will provide a much needed access to patients in India suffering with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths - 100mg/10ml and 500mg/50ml.

Dr Reddy's Laboratories Enters into an Agreement with Hetero to Market Hepatitis C Drug Sofosbufir 400 mg Tablets

Dr Reddy's Laboratories announced it has entered into an agreement with Hetero to allow the company to distribute and market chronic Hepatitis C drug Sofosbufir 400 mg tablets, manufactured by Hetero, under the brand name Resof in India. Clinical studies have indicated that Sofosbuvir 400 mg in combination with other agents achieved high cure rates while shortening treatment duration to 12 weeks and reducing or completely eliminating the need for Interferon injections, depending on the viral genotype. According to the World health Organization, close to 12 million Indians suffer from chronic Hepatitis C, a disease that can seriously affect the liver, leading to potentially lifethreatening complications, including liver cancer. Earlier this month, two citybased pharma players, Natco Pharma Limited and Hetero, got approval to manufacture and market generic Sofosbuvir tablets 400 mg, from the Drugs Controller General of India. Sofosbuvir is sold globally by Gilead Sciences Inc. under the Sovaldi brand name. Both the Indian companies had announced that they will market generic Sofosbuvir at a price of INR 19,900 for a bottle of 28 tablets.

Similar Private Companies By Industry

Company Name Region
Sven Genetech Limited Asia
Shilpa Organics Pvt. Ltd. Asia
Kemwell Biopharma Pvt. Ltd. Asia
Sami Labs Ltd. Asia
Vyome Biosciences Private Limited Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hetero Drugs Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at